Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Cardiomyopathy due to transthyretin-mediated amyloidosis
Last updated:
September 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Acne Vulgaris
Last updated:
August 29, 2022
Status:
Concluded without agreement
Manufacturer:
Pfizer Canada ULC
Indication:
Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients
Last updated:
August 26, 2022
Inqovi (decitabine-cedazuridine)
Status:
Concluded with an LOI
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Last updated:
August 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma in adult patients (in combination with fluoropyrimidine- and platinum-containing chemotherapy)
Last updated:
August 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Esophageal or gastroesophageal junction cancer, completely resected, adjuvant treatment in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)
Last updated:
August 25, 2022
Entresto (sacubitril/valsartan)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated:
August 17, 2022
Entresto (sacubitril/valsartan)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated:
August 17, 2022
Waymade-Trientine (trientine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Waymade Canada Inc
Indication:
Wilson's Disease
Last updated:
August 11, 2022
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Psoriatic Arthritis
Last updated:
August 8, 2022